Glaxosmithkline Pharmaceuticals Ltd Q1 FY27 Results Analysis: Revenue Surges 16.55%, Subsidiary PAT Loss Weighs

Glaxosmithkline Pharmaceuticals Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 938.44 Cr (+16.55% YoY) and PAT growth of +15.69% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

GLAXO reported strong 16.55% YoY revenue growth, recovering from supply chain disruptions and outpacing the IPM. Cost management improved material costs despite API price hikes. Concerns include higher other expenses and a subsidiary PAT loss.

Key Investment Insights

Key Positives

• Consolidated revenue grew 16.55% YoY to Rs.938.44 Cr, recovering from supply chain disruption.
• EBITDA margin expanded 29 bps YoY to 31.49% despite API price increases.
• Material cost as % of revenue improved to 34.23% from 35.78% YoY, demonstrating cost management.
• Revenue growth outpaced IPM growth of 10-11%, indicating market share gains.
• PAT grew 15.69% YoY (consolidated) and 23.76% (standalone).
• Supply chain constraints fully resolved, enabling strong growth.

Risk Factors

• Other expenses increased to 16.85% of revenue from 14.11% in Q1 FY26, pressuring margins.
• Subsidiary Biddle Sawyer recorded a PAT loss of Rs.16.15 Cr in Q1 FY27, reversing from a profit of Rs.24.16 Cr in FY26, dragging consolidated PAT.
• Revenue declined 5.71% QoQ, consistent with seasonality but still a sequential decline.